T Cell Avidity Dynamics in Tumor Immunology

T cell avidity reflects the overall strength of interaction between the T cell receptor and peptide–major histocompatibility complex on tumour cells, a central determinant of antitumour immunity. Both high- and low-avidity T cells coexist within the tumour microenvironment, yet their contributions to tumour control diverge: high-avidity clones often demonstrate potent immediate cytotoxicity but acquire a terminally exhausted phenotype, whereas low-avidity populations can sustain effector function, resist exhaustion and respond more robustly to checkpoint blockade. Avidity is not a fixed trait; it is shaped by antigen dose, co-stimulatory signals and repeated antigen exposure, driving a process akin to ‘avidity maturation’. The resulting heterogeneity in avidity influences T cell differentiation, exhaustion status and therapeutic responsiveness. Understanding these dynamics has profound implications for adoptive cell therapies, vaccine design and immune-checkpoint interventions, with the aim of selectively expanding T cell subsets that combine functional persistence with tumour reactivity.

Research from Nature Portfolio

Recent studies have demonstrated that low-avidity CD8+ T cells are the principal mediators of endogenous tumour control and the principal responders to checkpoint blockade. These cells exhibit a progenitor-like profile with reduced expression of exhaustion markers, whereas high-avidity counterparts show elevated exhaustion and suppressive features. A transcriptomic ‘avidity score’ was established to discriminate T cell populations in silico and to guide selection of low-avidity clones for immunotherapy. In parallel, methodological advances have enabled the quantification of functional avidity heterogeneity within both monoclonal and polyclonal T cell populations. By combining peptide titration assays with mathematical modelling, researchers revealed that functional avidity is distributed across a continuum rather than a single mean value, underscoring the need to characterise both average avidity and intrapopulation diversity when evaluating antitumour responses.

T Cell Avidity Dynamics in Tumor Immunology publication trend

The graph below shows the total number of articles in t cell avidity dynamics in tumor immunology across all publications each year (not limited to Nature Index journals).

Technical terms

T cell receptor (TCR): A surface molecule on T cells that recognises peptide–MHC complexes and initiates antigen-specific signalling.

Peptide–major histocompatibility complex (pMHC): A molecular complex on antigen-presenting cells or tumour cells presenting processed peptide antigens to TCRs.

Functional avidity: The sensitivity of a T cell to antigen, often measured by the lowest pMHC concentration that elicits a functional response.

T cell exhaustion: A state of dysfunctional differentiation in which T cells exhibit diminished effector function and sustained inhibitory receptor expression.

Checkpoint blockade: Therapeutic inhibition of inhibitory receptors or ligands (such as PD-1/PD-L1) to restore T cell activity against tumours.

References

1. Low-avidity T cells drive endogenous tumor immunity in mice and humans. Nature Immunology (2025).
2. Reactivation of low avidity tumor-specific CD8+ T cells associates with immunotherapeutic efficacy of anti-PD-1. Journal for ImmunoTherapy of Cancer (2023).
3. Functional Avidity: A Measure to Predict the Efficacy of Effector T Cells?. Journal of Immunology Research (2012).
4. High Peptide Dose Vaccination Promotes the Early Selection of Tumor Antigen-Specific CD8 T-Cells of Enhanced Functional Competence. Frontiers in Immunology (2020).
5. Heterogeneity assessment of functional T cell avidity. Scientific Reports (2017).